12 Nov 2021 16:17
For immediate release | 12 November 2021 |
ABCAM PLC
("Abcam" or "Company")
Total Voting Rights - Voting Rights and Capital
In conformity with the Disclosure Rules and Transparency Rules, provision 5.6.1, the Company notifies the market of the following: The Company's issued share capital consists of 228,776,756 Ordinary Shares of 0.2p each with voting rights. The Company does not hold any shares in Treasury.The above figure of 228,776,756 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
Date of Notification: 12 November 2021
For further information please contact:
Abcam | + 44 (0) 1223 696 000 |
Marc Perkins, Company Secretary
| |
Numis - Nominated Adviser & Joint Corporate Broker | + 44 (0) 20 7260 1000 |
Garry Levin / Freddie Barnfield / Duncan Monteith | |
J.P.Morgan Cazenove - Joint Corporate Broker James Mitford / Hemant Kapoor |
+44 (0) 20 7742 4000 |
Morgan Stanley - Joint Corporate Broker Tom Perry / Luka Kezic |
+44 (0) 20 425 8000 |
FTI Consulting Ben Atwell / Natalie Garland-Collins |
+44 (0) 20 3727 1000 |
Notes to Editors
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays and other research tools to address important targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.
Abcam's worldwide customer base of approximately 750,000 life science researchers uses Abcam's antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.
Founded in 1998 and headquartered in Cambridge, UK, the Company has served customers in more than 130 countries. Abcam's ordinary shares are listed on the London Stock Exchange (AIM: ABC) and its American Depositary Shares (ADSs) trade on the Nasdaq Global Market (Nasdaq: ABCM).
For more information, please visit corporate.abcam.com.